Daniel S. Lynch

Daniel S. Lynch brings extensive experience in senior executive leadership to his role as a CEO advisor. Since 2005, Mr. Lynch has advised and served as executive chair or member of the board of directors for several life science companies, including on the board of directors of bluebird bio, Inc., Blueprint Medicines Corp., Surface Oncology, SpringWorks Therapeutics and Translate Bio. Previously, Mr. Lynch served on the board of directors of DNIB Unwind, Inc. (formerly BIND Therapeutics, Inc.) from 2012 until its acquisition by Pfizer Inc. Mr. Lynch previously served on our board of directors from 2013-2020, and as Chair from 2013-2016. Mr. Lynch has served as a venture partner at Third Rock Ventures, a venture capital firm, since May 2013 and as an entrepreneur-in residence from May 2011 to May 2013, and now serves as a senior advisor. Prior to that, Mr. Lynch served as the Chief Financial Officer and then the Chief Executive Officer of ImClone Systems Inc. As ImClone’s chief executive officer, he led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX (Cetuximab), a novel cancer treatment. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. Mr. Lynch received a B.A. in Mathematics from Wesleyan University and a M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.